Lv3
265 积分 2021-06-21 加入
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study
1个月前
已完结
Interstitial lung disease in patients treated with antibody-drug conjugates: a review
1个月前
已完结
Advances in antibody-drug conjugate-based combination therapy strategies for non-small cell lung cancer
1个月前
已完结
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
1个月前
已完结
Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody-Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects
1个月前
已完结
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy
2个月前
已完结
Next-Generation Checkpoint Combinations: Optimizing PD-(L)1–Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings
2个月前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
2个月前
已完结
皖公网安备34019202002308
